版本:
中国

BRIEF-ZIOPHARM announces FDA acceptance of IND for CD33-specific CAR-T cell therapy

May 2 ZIOPHARM Oncology Inc

* Ziopharm oncology announces fda acceptance of ind for cd33-specific car-t cell therapy targeting relapsed/refractory acute myeloid leukemia

* Ziopharm oncology inc - investigator-initiated ind application to fda for a phase 1 trial infusing cd33-specific car(+) t therapy is now active

* Ziopharm oncology inc - first patient to be enrolled in study expected to begin treatment in q3 of 2017. Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐